Table 2. Main demographic and clinical characteristics of the groups studied.

		All patients (n = 123)	Efficacy study (n = 99)	Safety study(n = 113)
Male gender (%)		74.8	74.7	74.3
Age (years)*		41 (38–43)	40 (38–43)	40 (38–43)
Baseline weight (Kg)**		69.3±12	69.5±12	69.3±12
Baseline height (cm)**		170.7±8.2	170.9±8.4	170.7±8.3
HCV/HIV acquiring risk factor (%)	IDU	74	72.7	72.6
	Heterosexual	17.1	18.2	17.7
	Male homosexual	5.7	6.1	6.2
	Haemophiliac	0.8	1	0.9
	Other	2.4	2	2.7
AIDS (%)		42.2	40.4	42.5
HCV genotype (%)	1	43.9	45.4	44.2
	2	3.3	3	3.5
	3	34.1	32.3	32.7
	4	18.7	19.2	19.4
Baseline HCV-RNA>400000 IU/mL (%)		78.3	77.1	77.3
Baseline HCV-RNA>600000 IU/mL (%)		60	58.3	60
Baseline HCV-RNA>800000 IU/mL (%)		57.5	55.2	57.3
Fibrosis score, (%)	0–1	34.9	35.7	35.1
	2–4	65.1	64.3	64.9
Steatosis (%)		34	28.6	34.1
Baseline CD4 cell count (cells/mL)*		551 (430–733)	562 (434–760)	562 (415–787)
Baseline CD4 cell count ≤350 cells/mL (%)		14.8	15.3	16.2
Baseline HIV viral load≤200 copies/mL (%)		78.7	75.5	77.7
HAART (%)		84.5	82.8	84.1
RVR (%)		38.4	35.4	36.3
EVR (%)		75.4	73.9	74.7
SVR (%)		49.6	51.5	50
Discontinuation for toxicity (%)		11.4	0	12.8
Toxicity (%)		92.7	90.9	92
Anemia (%)		28.5	28.3	26.5
Neutropenia (%)		39.8	40.4	40.7
Thrombocytopenia (%)		39	38.4	39.8
Flu-like syndrome (%)		69.1	69.7	68.1
Headache (%)		15.4	16.2	15.9
Depression (%)		32.5	32.3	33.6
Gastrointestinal symptoms (%)		24.4	26.3	24.8
Lactic acidosis (%)		4.1	2	3.5

^*Median (25–75% interquartile range).

^**Mean±standard deviation.

HAART: Highly active antiretroviral therapy. EVR: Early virological response. RVR: Rapid virological response. SVR: Sustained virological response.